Ginkgo Bioworks
DNA
342 hedge funds and large institutions have $1.51B invested in Ginkgo Bioworks in 2024 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 110 increasing their positions, 93 reducing their positions, and 56 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 93
7% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 56
0% more funds holding
Funds holding: 342 → 342 (0)
0.06% less ownership
Funds ownership: 2.03% → 1.97% (-0.06%)
32% less capital invested
Capital invested by funds: $2.22B → $1.51B (-$713M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $4.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
+$31.1M |
| 2 |
Legal & General Group
London,
United Kingdom
|
+$12.8M |
| 3 |
ACM
AH Capital Management
Menlo Park,
California
|
+$5.62M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$3.88M |
| 5 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$3.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$63.2M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$11.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.96M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.26M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$3.07M |
DNA Hedge Fund Activity: Q1 2024 in Review
342 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q1 2024, worth a combined $1.51B — down 32% from $2.22B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new DNA positions and 56 closed out — a net gain of 4 holders — while 110 added to existing stakes and 93 trimmed.
The largest buyer was Glenview Capital Management, opening a new position worth an estimated $31.1M. The largest seller was Morgan Stanley, cutting an estimated $63.2M.
- 342 institutional investors held Ginkgo Bioworks (DNA) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $1.51B of Ginkgo Bioworks stock for Q1 2024, down 32% quarter-over-quarter.
- 60 funds opened new Ginkgo Bioworks positions in Q1 2024 and 56 closed out, a net change of +4 holders.
- The largest Ginkgo Bioworks buyer in Q1 2024 was Glenview Capital Management, an estimated $31.1M added.
- The largest Ginkgo Bioworks seller in Q1 2024 was Morgan Stanley, an estimated $63.2M sold.
Based on aggregated 13F filings for Q1 2024.